FDA Approves Pfizer's Trastuzumab Biosimilar

 
• By Dave Wallace

Pfizer’s approval for trastuzumab in the US marks the fourth FDA nod for a biosimilar rival to Genentech’s Herceptin original. However, while two of those biosimilar sponsors continue to be engaged in patent litigation with the originator, Pfizer and Mylan have both struck settlement deals.

PfizerSign
Pfizer Has Received A US Nod For Its Trazimera Rival To Herceptin • Source: Shutterstock

Pfizer’s Trazimera (trastuzumab-qyyp) biosimilar version of Genentech’s Herceptin has been approved by the US Food and Drug Administration (FDA).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products